In Wuhan Healthgen Biotechnology Corp. v. U.S. ITC, the Federal Circuit upheld an ITC ruling that Ventria Bioscience met the domestic industry requirement despite a modest investment in a patented bio
A Delaware court has ruled in favor of a biotech startup in a high-stakes lawsuit involving allegations of misappropriated trade secrets related to cancer treatment.
Examining the allegations against Valeant Pharma for using fraudulently obtained patent rights to overcharge the U.S. government.
Addressing a significant healthcare policy, the Biden administration appeals the reversal of a rule regarding insurers and drug coupons.
